This page was composed with the aid of generative artificial intelligence; it is partially curated.

Understanding Reports

Learn about the different types of reports generated by ZaroPGx and how to interpret them.

Report Types

PDF Clinical Report

The primary clinical report in PDF format, designed for healthcare providers.

Sections:

  • Executive Summary: Key findings and actionable recommendations

  • Gene Analysis: Detailed results for each pharmacogene

  • Clinical Guidelines: CPIC-based recommendations

  • Technical Details: Methodology and parameters used

  • References: Scientific citations and sources

Interactive HTML Report

A comprehensive web-based report with interactive features.

Features:

  • Interactive Tables: Sortable, filterable results

  • Visualizations: Charts, graphs, and diagrams

  • Detailed Annotations: Gene-specific information and explanations

  • Export Options: Download data in various formats

  • Search Functionality: Find specific genes or variants

Raw Data Files

Original outputs from analysis tools for further processing.

File Types:

  • PharmCAT HTML: Original PharmCAT report

  • PharmCAT JSON: Machine-readable results

  • PharmCAT TSV: Tab-separated data for spreadsheets

  • VCF Files: Processed variant calls

Report Structure

Executive Summary

Key Components:

  • Patient Information: Sample identifier and analysis date

  • Critical Findings: High-priority pharmacogenomic results

  • Actionable Recommendations: Clinical actions to consider

  • Risk Assessment: Overall risk profile for drug metabolism

Example:

EXECUTIVE SUMMARY
================

Patient ID: SAMPLE_001
Analysis Date: 2024-01-15
Reference Genome: GRCh38

CRITICAL FINDINGS:
- CYP2D6: Poor Metabolizer (*4/*4)
- CYP2C19: Intermediate Metabolizer (*1/*2)
- TPMT: Normal Metabolizer (*1/*1)

ACTIONABLE RECOMMENDATIONS:
- Avoid codeine and tramadol (CYP2D6 poor metabolizer)
- Consider reduced dosing for clopidogrel (CYP2C19 intermediate)
- Standard dosing appropriate for azathioprine (TPMT normal)

Gene Analysis Section

For Each Pharmacogene:

  • Diplotype: Star allele combination (e.g., *1/*2)

  • Phenotype: Functional classification (e.g., Intermediate Metabolizer)

  • Activity Score: Quantitative measure of enzyme activity

  • Clinical Significance: Impact on drug metabolism

  • Drug Interactions: Affected medications

  • Recommendations: Specific dosing guidance

Example Gene Entry:

CYP2D6 Analysis
===============

Diplotype: *4/*4
Phenotype: Poor Metabolizer
Activity Score: 0.0
Confidence: High

Clinical Significance:
- Significantly reduced enzyme activity
- Increased risk of adverse effects with standard dosing
- May require alternative medications

Affected Drugs:
- Codeine: Avoid (increased risk of toxicity)
- Tramadol: Avoid (increased risk of toxicity)
- Metoprolol: Consider reduced dosing
- Fluoxetine: Consider reduced dosing

Recommendations:
- Avoid codeine and tramadol
- Use alternative analgesics
- Consider reduced dosing for other CYP2D6 substrates
- Monitor for adverse effects

Understanding Star Alleles

Star Allele Notation

Format: *1/*2 (diplotype) or *1 (haplotype)

Common Alleles:

  • *1: Reference (wild-type) allele

  • *2, *3, *4, etc.: Variant alleles

  • *N: Novel or undefined alleles

  • *: No call or failed analysis

Examples:

  • *1/*1: Homozygous reference (normal metabolizer)

  • *1/*2: Heterozygous variant (intermediate metabolizer)

  • *2/*2: Homozygous variant (poor metabolizer)

  • *1/*17: Duplication (ultrarapid metabolizer)

Phenotype Classifications

Normal Metabolizer (NM):

  • Standard enzyme activity

  • Normal drug processing

  • Standard dosing appropriate

Intermediate Metabolizer (IM):

  • Reduced enzyme activity

  • Slower drug processing

  • May require dose adjustment

Poor Metabolizer (PM):

  • Significantly reduced activity

  • Very slow drug processing

  • Often requires alternative medications

Rapid Metabolizer (RM):

  • Increased enzyme activity

  • Faster drug processing

  • May require higher doses

Ultrarapid Metabolizer (UM):

  • Very high enzyme activity

  • Very fast drug processing

  • Often requires alternative medications

Clinical Recommendations

Recommendation Levels

Green (No Action):

  • Standard dosing appropriate

  • No special monitoring required

  • Normal drug response expected

Yellow (Consider Alternative):

  • Consider dose adjustment

  • Monitor for efficacy/adverse effects

  • May require alternative medications

Red (Avoid or Extreme Caution):

  • Avoid medication if possible

  • Use only with extreme caution

  • Consider alternative treatments

Blue (Additional Monitoring):

  • Standard dosing may be appropriate

  • Monitor closely for effects

  • Consider therapeutic drug monitoring

CPIC Guidelines

Clinical Pharmacogenomics Implementation Consortium (CPIC) Guidelines:

  • Evidence-based recommendations

  • Regularly updated with new evidence

  • Graded by strength of evidence

  • Specific to gene-drug pairs

Guideline Levels:

  • Level 1A: Strong evidence, high confidence

  • Level 1B: Strong evidence, moderate confidence

  • Level 2A: Moderate evidence, high confidence

  • Level 2B: Moderate evidence, moderate confidence

  • Level 3: Weak evidence, low confidence

Quality Metrics

Confidence Scores

High Confidence (≥90%):

  • Strong evidence for genotype

  • Multiple supporting variants

  • High-quality sequencing data

Moderate Confidence (70-89%):

  • Good evidence for genotype

  • Some supporting variants

  • Good-quality sequencing data

Low Confidence (<70%):

  • Weak evidence for genotype

  • Few supporting variants

  • Poor-quality sequencing data

Coverage Information

Coverage Depth:

  • High Coverage (≥30x): Reliable genotype calls

  • Medium Coverage (10-29x): Generally reliable

  • Low Coverage (<10x): May be unreliable

Coverage Breadth:

  • Complete: All target regions covered

  • Partial: Some regions missing

  • Incomplete: Many regions missing

Interpreting Results

Key Considerations

Clinical Context:

  • Consider patient’s current medications

  • Review medical history

  • Assess drug-drug interactions

  • Consider other genetic factors

Limitations:

  • Results are based on current knowledge

  • New variants may not be detected

  • Phenotype predictions are probabilistic

  • Clinical response may vary

Action Items:

  • Review with healthcare provider

  • Update medication list

  • Consider genetic counseling

  • Monitor for drug effects

Common Scenarios

CYP2D6 Poor Metabolizer:

  • Avoid codeine, tramadol

  • Consider alternative analgesics

  • Monitor for adverse effects

  • May require dose adjustment for other drugs

CYP2C19 Intermediate Metabolizer:

  • Consider reduced clopidogrel dosing

  • Monitor for efficacy

  • May require alternative antiplatelet therapy

  • Consider genetic testing for family members

TPMT Poor Metabolizer:

  • Avoid azathioprine, mercaptopurine

  • Use alternative immunosuppressants

  • Monitor for bone marrow toxicity

  • Consider genetic testing for family members

Export and Integration

FHIR Export

Fast Healthcare Interoperability Resources (FHIR):

  • Standard format for healthcare data

  • Compatible with EHR systems

  • Includes structured pharmacogenomic data

  • Supports clinical decision support

Export Process:

  1. Generate report

  2. Convert to FHIR format

  3. Export to FHIR server

  4. Integrate with EHR system

Data Formats

JSON Export:

  • Machine-readable format

  • Includes all analysis results

  • Compatible with other tools

  • Suitable for further processing

CSV Export:

  • Spreadsheet-compatible format

  • Includes key results

  • Easy to import into databases

  • Suitable for bulk analysis

Troubleshooting Reports

Common Issues

Missing Genes:

  • Check file coverage

  • Verify reference genome

  • Review analysis logs

  • Consider alternative tools

Low Confidence Results:

  • Check sequencing quality

  • Review coverage depth

  • Consider additional analysis

  • Consult with geneticist

Inconsistent Results:

  • Compare with other tools

  • Check analysis parameters

  • Review variant calls

  • Consider manual inspection

Getting Help

Documentation:

  • Review this guide

  • Check tool-specific documentation

  • Consult CPIC guidelines

  • Review scientific literature

Support:

  • Check system logs

  • Review error messages

  • Contact support team

  • Join community discussions

Next Steps